Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.